Randi Hagerman
Medical Director
MIND Institute
From this contributor
Diabetes drug delivers multiple benefits for people with fragile X syndrome
Researcher Randi Hagerman is a big proponent of metformin — a diabetes drug that she is testing in people with fragile X syndrome. In fact, Hagerman takes the drug herself as a preventive measure against cancer.
Diabetes drug delivers multiple benefits for people with fragile X syndrome
Drug trials for fragile X syndrome lead the way for autism
Several targeted trials on drugs that treat fragile X syndrome are under way. But accurate endpoints to measure the drugs’ effectiveness are crucial, argues developmental and behavioral pediatrician Randi Hagerman.
Drug trials for fragile X syndrome lead the way for autism
Explore more from The Transmitter
U.S. national primate research centers face an uncertain future
The facilities were meant to last 100 years. Four decades shy of that mark, amid flatlined funds and mounting political pressure, their directors are trying to find a path forward.
U.S. national primate research centers face an uncertain future
The facilities were meant to last 100 years. Four decades shy of that mark, amid flatlined funds and mounting political pressure, their directors are trying to find a path forward.
What if nonhuman primate research goes away?
As the U.S. government takes steps to stop using nonhuman primates in research, The Transmitter investigates what that shift could mean for neuroscience.
What if nonhuman primate research goes away?
As the U.S. government takes steps to stop using nonhuman primates in research, The Transmitter investigates what that shift could mean for neuroscience.
The neuroscience questions that need nonhuman primates
The Transmitter asked 17 neuroscientists what questions might remain unanswered if support for nonhuman primate research continues to decline.
The neuroscience questions that need nonhuman primates
The Transmitter asked 17 neuroscientists what questions might remain unanswered if support for nonhuman primate research continues to decline.